Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556

Citation
T. Brenner et al., Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556, EXP NEUROL, 154(2), 1998, pp. 489-498
Citations number
50
Categorie Soggetti
Neurosciences & Behavoir
Journal title
EXPERIMENTAL NEUROLOGY
ISSN journal
00144886 → ACNP
Volume
154
Issue
2
Year of publication
1998
Pages
489 - 498
Database
ISI
SICI code
0014-4886(199812)154:2<489:SOEAEB>2.0.ZU;2-0
Abstract
Tyrosine kinase blockers from the AG 126/AG-556 tyrphostin family are shown to inhibit the lipopolysaccharide (LPS)-induced production of tumor necros is factor alpha (TNF alpha), nitric oxide (NO), and prostaglandin E-2 (PGE( 2)) in primary rat astrocytes cultures. The tyrphostin AG-556 which was pre viously shown to be effective against sepsis in mice and dogs also show exc ellent efficacy in inhibiting experimental autoimmune encephalomyelitis (EA E) in mice. AG-556 does not block the activation of JNK/SAPK and of p38/HOG and therefore seems to act at a target down stream to these kinases which is activated in stress or at a target on an obligatory parallel pathway. Th ese findings together with previous results showing inhibition of sepsis in mice and dogs suggest that protein tyrosine kinase (PTK) blockers of the A G-556 family may be considered in the management of human autoimmune disord ers such as multiple sclerosis (MS). (C) 1998 Academic Press.